期刊文献+
共找到14篇文章
< 1 >
每页显示 20 50 100
老年肝硬化患者外周血炎性细胞因子表达对照分析
1
作者 侯春阳 马玉梅 《中国老年保健医学》 2015年第4期69-69,71,共2页
目的对照分析老年乙肝(HBV)肝硬化患者外周血炎性细胞因子指标表达。方法连续选择2014年1月至12月前往沈阳市第六人民医院门诊就诊的老年HBV肝硬化患者34例,对照组为同年参加我院健康体检结果正常的老年人37例,比较两组对象外周血炎性... 目的对照分析老年乙肝(HBV)肝硬化患者外周血炎性细胞因子指标表达。方法连续选择2014年1月至12月前往沈阳市第六人民医院门诊就诊的老年HBV肝硬化患者34例,对照组为同年参加我院健康体检结果正常的老年人37例,比较两组对象外周血炎性细胞因子[白介素-6(IL-6),白介素-8(IL-8),白介素-10(IL-10),γ-干扰素(IFN-γ)及肿瘤坏死因子-α(TNF-α)]指标表达现况。结果老年HBV肝硬化患者组外周血IL-6,IL-8,IL-10,IFN-γ及TNF-α表达浓度均明显高于对照组(P<0.05或P<0.01)。结论老年HBV肝硬化患者存在明确外周血炎性细胞因子指标表达异常。 展开更多
关键词 肝硬化/乙肝 老年 炎性细胞因子 外周血
下载PDF
Liver stiffness in the hepatitis B virus carrier:A non-invasive marker of liver disease influenced by the pattern of transaminases 被引量:43
2
作者 Filippo Oliveri Barbara Coco +5 位作者 Pietro Ciccorossi Piero Colombatto Veronica Romagnoli Beatrice Cherubini Ferruccio Bonino Maurizia Rossana Brunetto 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第40期6154-6162,共9页
AIM: To investigate the usefulness of transient elastography by Fibroscan (FS), a rapid non-invasive technique to evaluate liver fibrosis, in the management of chronic hepatitis B virus (HBV) carriers. METHODS: ... AIM: To investigate the usefulness of transient elastography by Fibroscan (FS), a rapid non-invasive technique to evaluate liver fibrosis, in the management of chronic hepatitis B virus (HBV) carriers. METHODS: In 297 consecutive HBV carriers, we studied the correlation between liver stiffness (LS), stage of liver disease and other factors potentially influencing FS measurements. In 87 chronic hepatitis B (CriB) patients, we monitored the FS variations according to the spontaneous or treatment-induced variations of biochemical activity during follow-up. RESULTS: FS values were 12.3 ± 3.3 kPa in acute hepatitis, 10.3 ± 8.8 kPa in chronic hepatitis, 4.3 ± 1.0 kPa in inactive carriers and 4.6 ± 1.2 kPa in blood donors. We identified the cut-offs of 7.5 and 11.8 kPa for the diagnosis of fibrosis ≥S3 and cirrhosis respectively, showing 93.9% and 86.5% sensitivity, 88.5% and 96.3% specificity, 76.7% and 86.7% positive predictive value (PPV), 97.3% and 96.3% negative predictive value (NPV) and 90.1% and 94.2% diagnostic accuracy. At multivariate analysis in 171 untreated carriers, fibrosis stage (t = 13.187,P 〈 0.001), active vs inactive HBV infection (t = 6.437, P 〈 0.001), alanine aminotransferase (ALT) (t = 4.740, P 〈 0.001) and HBV-DNA levels (t = -2.046, P = 0.042) were independently associated with FS. Necroinflammation score (t = 2.158, 〉 10/18 vs ≤ 10/18, P = 0.035) and ALT levels (t = 3.566, P =0.001) were independently associated with LS in 83 untreated patients without cirrhosis and long-term biochemical remission (t = 4.662, P 〈 0.001) in 80 treated patients. During FS monitoring (mean followup 19.9 ± 7.1 mo) FS values paralleled those of ALT in patients with hepatitis exacerbation (with 1.2 to 4.4-fold increases in Crib patients) and showed a progressive decrease during antiviral therapy. CONCLUSION: FS is a non-invasive tool to monitor liver disease in chronic HBV carriers, provided that the pattern of biochemical activity is taken into account. In the inactive carrier, it identifies non-HBV-related causes of liver damage and transient reactivations. In CHB patients, it may warrant a more appropriate timing of control liver biopsies. 展开更多
关键词 Liver elastography Liver fibrosis CIRRHOSIS Hepatitis B virus Chronic hepatitis B
下载PDF
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection 被引量:24
3
作者 Ingolf Schiefke Andreas Fach +5 位作者 Marcus Wiedmann Andreas V.Aretin Eva Schenker Gudrun Borte Manfred Wiese Joachim Moessner 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第12期1843-1847,共5页
AIM: Previous studies suggest that loss of bone mineral density (BMD) frequently occurs in patients with chronic viral liver disease, presenting with histologically proven liver cirrhosis. However, little is known abo... AIM: Previous studies suggest that loss of bone mineral density (BMD) frequently occurs in patients with chronic viral liver disease, presenting with histologically proven liver cirrhosis. However, little is known about the occurrence of bone disease in non-cirrhotic patients with chronic hepatitis B or C. Therefore, it was the aim of this study to evaluate this particular population for BMD and bone turnover markers. METHODS: Biochemical markers of bone turnover and BMD were measured in 43 consecutive patients with HCV (n = 30) or HBV (n = 13) infection without histological evidence for liver cirrhosis. Mean age was 49 years (range 26-77 years). BMD was measured by dual X-ray absorptiometry in the femoral neck (FN) and the lumbar spine (LS) region. In addition, bone metabolism markers were measured. RESULTS: BMD was lowered in 25 (58%) of the patients with chronic hepatitis B or C (FN; 0.76 (0.53-0.99); LS: 0.96 (0.62-1.23) g/cm2). Eight (32%) osteopenic patients were diagnosed with osteoporosis. Bone-specific alkaline phosphatase (P= 0.005) and intact parathyroid hormone (iPTH) (P = 0.001) were significantly elevated in the more advanced stages of fibrosis. Mean T-score value was lower in patients with chronic hepatitis C as compared to patients suffering from chronic hepatitis B; however, the difference was not statistically significant (P= 0.09). CONCLUSION: There was a significantly reduced BMD in non-cirrhotic patients with chronic hepatitis B or C infection. Alterations of bone metabolism already occurred in advanced liver fibrosis without cirrhosis. According to our results, these secondary effects of chronic viral hepatitis should be further investigated. 展开更多
关键词 Bone density Chronic viral hepatitis Non cirrhotic patients
下载PDF
Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis 被引量:7
4
作者 Koichi Honda Masataka Seike +4 位作者 Shin-ichiro Maehara Koichiro Tahara Hideaki Anai Akira Moriuchi Toyokichi Muro 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第20期2586-2590,共5页
A 69-year-old man was admitted to our hospital in October 2003,for further examination of two liver tumors.He was diagnosed with hepatocellular carcinoma(HCC) arising from decompensated hepatitis B virus(HBV)-related ... A 69-year-old man was admitted to our hospital in October 2003,for further examination of two liver tumors.He was diagnosed with hepatocellular carcinoma(HCC) arising from decompensated hepatitis B virus(HBV)-related cirrhosis.Long-term lamivudine administration improved liver function dramatically despite repeated treatment for HCC.His Child-Pugh score was 9 points at start of lamivudine treatment,improving to 5 points after 1 year.His indocyanine green at 15 min after injection test score was 48%before lamivudine treat-ment,improving to 22%after 2 years and to 5%after 4 years.Radiofrequency ablation controlled the HCC foci and maintained his liver function.In April 2009,abdominal computed tomography revealed a tumor thrombus in the right portal vein.Since his indocyanine green test results had improved to less than 10%,we performed a right hepatectomy,which was successful.To our knowledge,there have been no documented reports of patients undergoing successful right hepatectomy for HCC arising from decompensated cirrhosis.The findings observed in our patient indicate the importance of nucleoside analogs for treating HBV-related HCC. 展开更多
关键词 Hepatitis B virus LAMIVUDINE Hepatocellular carcinoma Decompensated cirrhosis HEPATECTOMY
下载PDF
Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy 被引量:10
5
作者 Zhi-Jun Bao De-Kai Qiu +5 位作者 Xiong Ma Zhu-Ping Fan Gan-Sheng Zhang Yi-Qin Huang Xiao-Feng Yu Min-De Zeng 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第21期3003-3008,共6页
AIM:To evaluate the health-related quality of life (HRQOL) based on the Chinese version of SF-36 and Chronic Liver Disease Questionnaire (CLDQ) in subjects with chronic hepatitis B,liver cirrhosis,including patients w... AIM:To evaluate the health-related quality of life (HRQOL) based on the Chinese version of SF-36 and Chronic Liver Disease Questionnaire (CLDQ) in subjects with chronic hepatitis B,liver cirrhosis,including patients with minimal hepatic encephalopathy (MHE). METHODS:The SF-36 and CLDQ were administered to 160 healthy volunteers,20 subjects with chronic hepatitis B and 106 patients with cirrhosis (33 cases exhibited MHE). HRQOL scores were compared among the different study groups. The SF-36 includes eight health concepts:physical functioning,role-physical,body pain,general health,vitality,social functioning,role-emotion,and mental health. Six domains of CLDQ were assessed:abdominal symptoms,fatigue,systemic symptoms,activity,emotional function and worry. RESULTS:Compared with healthy controls (96.9 ± 4.5,86.6 ± 18.4,90.1 ± 12.5,89.0 ± 5.7,87.5 ± 4.3,95.8 ± 7.1,88.5 ± 15.9,88.7 ± 5.2 in SF-36 and 6.7 ± 0.5,6.1 ± 0.6,6.3 ± 0.6,6.5 ± 0.5,6.3 ± 0.5,6.8 ± 0.4 in CLDQ),patients with chronic hepatitis B (86.3 ± 11.0,68.8 ± 21.3,78.9 ± 14.4,60.8 ± 10.5,70.8 ± 8.6,76.1 ± 12.6,50.0 ± 22.9,72.2 ± 10.6 and 5.5 ± 1.0,4.5 ± 1.0,5.2 ± 1.1,5.3 ± 0.9,4.8 ± 0.9,4.9 ± 1.0) and cirrhosis (52.8 ± 17.4,32.8 ± 27.9,61.6 ± 18.9,30.2 ± 18.3,47.9 ± 20.1,54.0 ± 19.2,28.9 ± 26.1,51.1 ± 17.8 and 4.7 ± 1.2,3.9 ± 1.2,4.7 ± 1.2,4.7 ± 1.3,4.7 ± 1.0,4.4 ± 1.1) had lower HRQOL on all scales of the SF-36 and CLDQ (P < 0.01 for all). Increasing severity of liver cirrhosis (based on the Child-Pugh score/presence or absence of MHE) was associated with a decrease in most components of SF-36 and CLDQ,especially SF-36.CONCLUSION:The Chinese version of SF-36 along with CLDQ is a valid and reliable method for testing MHE in patients with liver cirrhosis. Cirrhosis and MHE are associated with decreased HRQOL. 展开更多
关键词 Minimal hepatic encephalopathy Liver cirrhosis Health-related quality of life Chronic hepatitis B CHINESE
下载PDF
Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients 被引量:31
6
作者 Xu-Dong Liu Jian-Lin Wu +2 位作者 Jian Liang Tao Zhang Qing-Shou Sheng 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第22期2784-2792,共9页
AIM: To establish a simple model consisting of the rou- tine laboratory variables to predict both minimal fibrosis and cirrhosis in chronic hepatitis B virus (HBV)-infected patients. METHODS: We retrospectively in... AIM: To establish a simple model consisting of the rou- tine laboratory variables to predict both minimal fibrosis and cirrhosis in chronic hepatitis B virus (HBV)-infected patients. METHODS: We retrospectively investigated 114 chron- ic HBV-infected patients who underwent liver biopsy in two different hospitals. Thirteen parameters were analyzed by step-wise regression analysis and correla- tion analysis. A new fibrosis index [globulin/platelet (GP) model] was developed, including globulin (GLOB) and platelet count (PLT). GP model = GLOB (g/mL) x 100/PLT (x 109/L). We evaluated the receiver operating characteristics analysis used to predict minimal fibrosis and compared six other available models. RESULTS: Thirteen clinical biochemical and hemato- logical variables [sex, age, PLT, alanine aminotransfer- ase, aspartate aminotransferase (AST), albumin, GLOB, total bilirubin (T.bil), direct bilirubin (D.bil), glutamyl-transferase, alkaline phosphatase, HBV DNA and pro- thrombin time (PT)] were analyzed according to three stages of liver fibrosis (F0-F1, F2-F3 and F4). Bivariate Spearman's rank correlation analysis showed that six variables, including age, PLT, T.bil, D.bil, GLOB and PT, were correlated with the three fibrosis stages (FS). Cor- relation coefficients were 0.23, -0.412, 0.208, 0.220, 0.314 and 0.212; and P value was 0.014, 〈 0.001, 0.026, 0.018, 0.001 and 0.024, respectively. Univariate analysis revealed that only PLT and GLOB were signifi- cantly different in the three FS (PLT: F = 11.772, P 〈 0.001; GLOB: F = 6.612, P = 0.002). Step-wise multiple regression analysis showed that PLT and GLOB were also independently correlated with FS (R2 = 0.237). By Spearman's rank correlation analysis, GP model was significantly correlated with the three FS (r = 0.466, P 〈 0.001). The median values in F0-F1, F2-F3 and F4 were 1.461, 1.720 and 2.634. Compared with the six available models (fibrosis index, AST-platelet ratio, FIB-4, fibrosis-cirrhosis index and age-AST model and age-PLT ratio), GP model showed a highest correlation coefficient. The sensitivity and positive predictive value at a cutoff value 〈 1.68 for predicting minimal fibrosis F0-F1 were 72.4% and 71.2%, respectively. The speci- ficity and negative predictive value at a cutoff value 〈 2.53 for the prediction of cirrhosis were 84.5% and 96.7%. The area under the curve (AUC) of GP model for predicting minimal fibrosis and cirrhosis was 0.762 [95% confidence interval (CI): 0.676-0.848] and 0.781 (95% CI: 0.638-0.924). Although the differences were not statistically significant between GP model and the other models (P all 〉 0.05), the AUC of GP model was the largest among the seven models. CONCLUSION: By establishing a simple model using available laboratory variables, chronic HBV-infected patients with minimal fibrosis and cirrhosis can be di- agnosed accurately, and the clinical application of this model may reduce the need for liver biopsy in HBV- infected patients. 展开更多
关键词 GLOBULIN PLATELET Globulin/platelet model Liver fibrosis Noninvasive fibrosis biomarker Chronichepatitis B virus
下载PDF
Future prospectives for the management of chronic hepatitis B 被引量:14
7
作者 WF Leemans HLA Janssen RA de Man 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第18期2554-2567,共14页
Chronic hepatitis B virus infection affects about 400 million people around the globe and causes approximately a million deaths a year. Since the discovery of interferon-α as a therapeutic option the treatment of hep... Chronic hepatitis B virus infection affects about 400 million people around the globe and causes approximately a million deaths a year. Since the discovery of interferon-α as a therapeutic option the treatment of hepatitis B has evolved fast and management has become increasingly complicated. The amount of viral replication reflected in the viral load (HBV-DNA) plays an important role in the development of cirrhosis and hepatocellular carcinoma. The current treatment modalities for chronic hepatitis B are immunomodulatory (interferons) and antiviral suppressants (nucleoside and nucleotide analogues) all with their own advantages and limitations. An overview of the treatment efficacy for both immunomodulatory as antiviral compounds is provided in order to provide the clinician insight into the factors influencing treatment outcome. With nucleoside or nucleotide analogues suppression of viral replication by 5-7 log10 is feasible, but not all patients respond to therapy. Known factors influencing treatment outcome are viral load, ALT levels and compliance. Many other factors which might influence treatment are scarcely investigated. Identifying the factors associated with response might result in stopping rules, so treatment could be adapted in an early stage to provide adequate treatment and avoid the development of resistance. The efficacy of compounds for the treatment of mutant virus and the cross-resistance is largely unknown. However, genotypic and phenotypic testing as well as small clinical trials provided some data on efficacy in this population. Discontinuation of nucleoside or nucleotide analogues frequently results in viral relapse; however, some patients have a sustained response. Data on the risk factors for relapse are necessary in order to determine when treatment can be discontinued safely. In conclusion: chronic hepatitis B has become a treatable disease; however, much research is needed to tailor therapy to an individual patient, to predict the sustainability of response and determine the best treatment for those failing treatment. 展开更多
关键词 Hepatitis B virus Cirrhosis Treatment Interferon Nucleoside analogues Nucleotide analogues LAMIVUDINE ADEFOVIR ENTECAVIR TELBIVUDINE TENOFOVIR Resistance Genotype
下载PDF
Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein 被引量:18
8
作者 Yan-Ming Zhou Jia-Mei Yang +5 位作者 Bin Li Zheng-Feng Yin Feng Xu Bin Wang Peng Liu Zhi-Min Li 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第14期2251-2254,共4页
AIM:To explore clinicopathologic characteristics of intrahepatic cholangiocarcinoma (ICC) in patients with positive serum a-fetoprotein (AFP). METHODS:One hundred and thirty one patients who underwent surgical dissect... AIM:To explore clinicopathologic characteristics of intrahepatic cholangiocarcinoma (ICC) in patients with positive serum a-fetoprotein (AFP). METHODS:One hundred and thirty one patients who underwent surgical dissection for pathologically confirmed ICC were divided into a positive AFP (> 20 ng/mL) group (n = 32) and a negative AFP group (n = 99), whose clinicopathologic features were analyzed and compared. RESULTS:The positive rate of HBsAg and liver cirrhosis of the positive AFP group was higher than that of the negative AFP group, while the positive rate of CA19-9 (> 37 U/mL) and the lymph node metastasis rate was lower. CONCLUSION:ICC patients with positive AFP share many clinicopathologic similarities with hepatocellular carcinoma. 展开更多
关键词 Intrahepatic cholangiocarcinoma A-fetopro tein Hepatitis B virus Liver cirrhosis Hepatic stem cells
下载PDF
Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C 被引量:5
9
作者 Rudolf E Stauber Carolin Lackner 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第32期4287-4294,共8页
Assessment of hepatic fibrosis is important for determining prognosis,guiding management decisions,and monitoring disease. Histological evaluation of liver biopsy specimens is currently considered the reference test f... Assessment of hepatic fibrosis is important for determining prognosis,guiding management decisions,and monitoring disease. Histological evaluation of liver biopsy specimens is currently considered the reference test for staging hepatic fibrosis. Since liver biopsy carries a small but significant risk,noninvasive tests to assess hepatic fibrosis are desirable. This editorial gives an overview on noninvasive methods currently available to determine hepatic fibrosis and their diagnostic accuracy for predicting significant fibrosis and cirrhosis in chronic hepatitis C. Based on available data,the performance of simple tests derived from routine laboratory parameters appears to be similar to that of more complex and expensive fibrosis panels. Transient elastography seems more accurate than blood tests for diagnosing cirrhosis. 展开更多
关键词 Noninvasive fibrosis tests Significant fibrosis CIRRHOSIS Biomarkers Transient elastography
下载PDF
Hepatitis B virus genotypes in southwest Iran: Molecular, serological and clinical outcomes 被引量:4
10
作者 Anahita Mojiri Abbas Behzad-Behbahani +17 位作者 Mehdei Saberifirozi Maryam Ardabili Mahmood Beheshti Marjan Rahsaz Mehrdad Banihashemi Negar Azarpira Bita Geramizadeh Baharak Khadang Afsaneh Moaddeb Mojgan Ghaedi Tahereh Heidari Ardeshir Torab Alireza Salah Saeid Amirzadeh Zahra Jowkar Davood Mehrabani Samad Amini-Bavil-Olyaee Mohammad Ali Dehyadegari 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第10期1510-1513,共4页
AIM: To investigate the associations of hepatitis B virus (HBV) genotype with HBeAg and anti-HBe status, alanine aminotransferase (ALT) levels and HBV-DNA detection in different groups of HBV-infected patients in sout... AIM: To investigate the associations of hepatitis B virus (HBV) genotype with HBeAg and anti-HBe status, alanine aminotransferase (ALT) levels and HBV-DNA detection in different groups of HBV-infected patients in southwest Iran. METHODS: A total of 89 HBsAg-positive serum samples were collected from the same number of patients. All sera were then investigated to determine HBV DNA and serological markers. For all the polymerase chain reaction (PCR)-positive samples, biochemical, histopathological assays and genotyping were also performed. RESULTS: Genotype D was the only type of HBV foundin different clinical forms of acute and chronic infections. There was a high prevalence of HBeAg-negative HBV- infected patients with chronic hepatitis (52.7%). Out of 55 patients with chronic hepatitis, seven (12.7%) were diagnosed with cirrhosis. A significant association between the presence of anti-HBe antibody and an increase in ALT level, among either HBeAg-negative (P = 0.01) or HBeAg-positive (P = 0.026) patients, was demonstrated. No significant differences were observed between the clinical outcomes of HBeAg-positive and -negative individuals (P = 0.24). CONCLUSION: Genotype D has been recognized as the only type of HBV found in different clinical forms of HBV infections, including cirrhosis, among the residents of southwest Iran. Anti-HBe possibly plays a role in disease progression in some patients with chronic hepatitis, at least for a period of disease. 展开更多
关键词 Hepatitis B virus-D CIRRHOSIS Iran Anti-HBe Polymerase chain reaction
下载PDF
Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics 被引量:1
11
作者 Yock-Young Dan Chun-Tao Wai +3 位作者 Yin-Mei Lee Dede Selamat Sutedja Bee-Leng Seer Seng-Gee Lim 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第28期4344-4350,共7页
AIM: We set to determine factors that determine clinical severity after the development of resistance.METHODS: Thirty-five Asian patients with genotypic lamivudine resistance were analyzed in three groups: 13/35 (... AIM: We set to determine factors that determine clinical severity after the development of resistance.METHODS: Thirty-five Asian patients with genotypic lamivudine resistance were analyzed in three groups: 13/35 (37%) were non-cirrhotics with normal pre-treatment ALT (Group IA), 12/35 (34%) were non-cirrhotics with elevated pre-treatment ALT (Group IB), and 10/35 (29%) were cirrhotics (Group II). Patients were followed for a median of 98 wk (range 26-220) after the emergence of genotypic resistance.RESULTS: Group IA patients tended to retain normal ALT. Group IB patients showed initial improvement of ALT with lamivudine but 9/12 patients (75%) developed abnormal ALT subsequently. On follow-up however, this persisted in only 33%. Group II patients also showed improvement while on treatment, but they deteriorated with the emergence of resistance with 30% death from decompensated liver disease. Pretreatment ALT levels and CPT score (in the cirrhotic group) were predictive of clinical resistance and correlated with peak ALT levels and CPT score.CONCLUSION: The phenotype of lamivudine-resistant HBV correlated with the pretreatment phenotype. The clinical course was generally benign in non-cirrhotics. However, cirrhotics had a high risk of progression and death (30%) with the development of lamivudine resistance. 展开更多
关键词 Lamivudine resistance YMDD mutants Hepatitis B treatment Nucleoside analog
下载PDF
OBSERVATION ON THE EFFECT OF MOXIBUSTION ON HYPERBILIRUBINEMIA IN HEPATITIS B TYPE CIRRHOSIS PATIENTS 被引量:1
12
作者 程井军 孙国杰 《World Journal of Acupuncture-Moxibustion》 2004年第4期12-15,共4页
Objective: To study the effect of moxibustion on hyperbilirubinemia in hepatitis B cirrhosis patients. Methods: 56 cases of inpatients with hepatitis B cirrhosis were divided into treatment group (n=27) and control gr... Objective: To study the effect of moxibustion on hyperbilirubinemia in hepatitis B cirrhosis patients. Methods: 56 cases of inpatients with hepatitis B cirrhosis were divided into treatment group (n=27) and control group (n=29) randomly. All the patients of these two groups were given with routine expectant treatment including administration of medicines (Bifendate, Eessentiale, Potenline, etc) for protecting liver functions, reducing the level of alanine aminotransferase (ALT), etc., and in the meantime, patients of the treatment group were also treated with moxibustion of Zusanli (足三里 ST 36), Taichong (太冲 LR 3) and Sanyinjiao (三阴交 SP 6), once daily, continuously for 4 weeks. Results: After 4 weeks of treatment, of the 27 and 29 cases of treatment and control group, 23 and 10 patients had improvement in clinical symptoms, 4 and 19 failed, with the total effective rates being 85.18% and 34.48% respectively. Serum total bilirubin (TBil) contents of treatment and control groups decreased significantly, and the level of TBil in the treatment group was significantly lower than that in the control group (P<0.01). Conclusion: Moxibustion is an effective remedy in relieving hyperbilirubinemia and improving clinical symptoms in the treatment of hepatitis B cirrhosis patients. 展开更多
关键词 Hyperbilirubinemia Hepatitis B cirrhosis Moxibustion
下载PDF
Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients 被引量:4
13
作者 Lei-Jia Li Xiao-Ying Wu +8 位作者 Si-Wei Tan Zi-Jun Xie Xue-Mei Pan Shun-Wen Pan Wu-Ri-Na Bai Hai-Jiao Li Hui-Ling Liu Jie Jiang Bin Wu 《Gastroenterology Report》 SCIE EI 2019年第6期434-443,I0002,共11页
Background:Long non-coding RNAs(lncRNAs)have been applied as biomarkers in many diseases.However,scarce biomarkers are available in single lncRNA differential expression associated with different clinical stages of li... Background:Long non-coding RNAs(lncRNAs)have been applied as biomarkers in many diseases.However,scarce biomarkers are available in single lncRNA differential expression associated with different clinical stages of liver cirrhosis(LC).The aim of the study is to identify some lncRNAs that can serve as non-invasive sensitive biomarkers for early diagnosis and grade of LC.Methods:Blood lncRNA expression was evaluated in three independent cohorts with 305 participants including healthy controls,hepatitis B virus(HBV)carriers,and patients with chronic hepatitis B(CHB)or LC.First,candidate lncRNAs were screened by CapitalBiotech microarray to diagnose cirrhosis.Quantitative reverse-transcriptase polymerase chain reaction was then used to investigate the expression of selected lncRNAs in the whole group of cirrhosis and different Child–Pugh classes.Ultimately,the diagnostic accuracy of the promising biomarker was examined and validated via Mann–Whitney test and receiver-operating characteristics analysis.Results:Lnc-TCL6 was identified as a sensitive biomarker for early diagnosis of LC(Child–Pugh A)compared with healthy controls(area under the ROC curve[AUC]=0.636),HBV carriers(AUC=0.671),and CHB patients(AUC=0.672).Furthermore,lnc-TCL6 showed a favourable capacity in discriminating among different Child–Pugh classes(AUC:0.711–0.837).Compared with healthy controls,HBV carriers,and CHB patients,the expression of lnc-TCL6 was obviously up-regulated in Child–Pugh A patients and,conversely,significantly down-regulated in Child–Pugh C patients.Conclusions:Lnc-TCL6 is a novel potential biomarker for early diagnosis of LC and is a possible predictor of disease progression. 展开更多
关键词 long non-coding RNAs Lnc-TCL6 BIOMARKER liver cirrhosis Child–Pugh classification
原文传递
Clinical study of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B 被引量:1
14
作者 NIE Lu ZHANG Juanli 《Journal of Acupuncture and Tuina Science》 CSCD 2022年第3期199-205,共7页
Objective:To investigate the efficacy and possible mechanism of action of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B(CHB).Methods:Ninety pati... Objective:To investigate the efficacy and possible mechanism of action of warm needling moxibustion combined with entecavir in the treatment of compensated cirrhosis due to chronic hepatitis B(CHB).Methods:Ninety patients were randomly divided into a control group and an observation group,with 45 patients in each group.The control group was given oral entecavir,and the observation group was given additional warm needling moxibustion.The serum alanine transaminase(ALT),aspartate transaminase(AST),albumin(ALB)levels,portal vein internal diameter,splenic vein internal diameter,spleen thickness,and liver hardness were compared before and after treatment.The serum hyaluronic acid(HA),laminin(LN),procollagen typeⅢ(PCⅢ),typeⅣcollagen(Ⅳ-C),interleukin(IL)-21,and platelet-derived growth factor(PDGF)levels were also measured.Results:After treatment,the serum ALT and AST levels decreased(P<0.05),and the serum ALB levels increased(P<0.05)in both groups.The serum ALT and AST levels were lower in the observation group than in the control group(P<0.05),and the ALB level was higher in the observation group(P<0.05).The portal vein internal diameter,splenic vein internal diameter,spleen thickness,and liver hardness values were reduced in both groups after treatment(P<0.05),and were lower in the observation group than in the control group(P<0.05).The serum HA,LN,PCⅢ,andⅣ-C levels were reduced in both groups(P<0.05),and were lower in the observation group than in the control group(P<0.05).In the control group,the serum IL-21 level decreased(P<0.05),but the serum PDGF level did not change significantly(P>0.05);in the observation group,the serum IL-21 and PDGF levels decreased significantly(P<0.05)and were lower than those in the control group(P<0.05).Conclusion:Warm needling moxibustion combined with entecavir treatment can improve liver function,reduce the inner diameters of the portal vein and splenic vein,spleen thickness,and liver hardness,and improve liver fibrosis indicators in patients with CHB cirrhosis,which may be related to the reduction of serum IL-21 and PDGF levels. 展开更多
关键词 Acupuncture-moxibustion Therapy Warm Needling Therapy Acupuncture Medication Combined ENTECAVIR Hepatitis B Chronic Liver Cirrhosis Liver Function Tests
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部